TScan Therapeutics to Participate in Upcoming Investor Conferences

About this update from Tscan Therapeutics, Inc.

WALTHAM, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: Webcasts of the fireside chat and presentation will be available on the “ Events and Presentations ” section of the Company’s website at  ir.tscan.com . Archived replays of the webcasts will be available on the Company’s website for 90 days following the events. About TScan Therapeutics, Inc. TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA ™  Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T ™  Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs. Contacts Heather Savelle TScan Therapeutics, Inc. VP, Investor Relations 857-399-9840 [email protected] Melissa Forst Argot Partners 212-600-1902 [email protected]

View stock analysis, news, and events for Tscan Therapeutics, Inc.